149 related articles for article (PubMed ID: 38162638)
21. Eosinopenia in Children following Traumatic Intracranial Hemorrhage Is Associated with Poor Prognosis and Prolonged Hospital Admission.
Hori YS; Fukuhara T; Aoi M; Namba Y
Pediatr Neurosurg; 2016; 51(2):57-60. PubMed ID: 26636657
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
[TBL] [Abstract][Full Text] [Related]
23. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
24. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.
Sun Y; Jin L; Dian Y; Shen M; Zeng F; Chen X; Deng G
EClinicalMedicine; 2023 May; 59():101981. PubMed ID: 37193346
[TBL] [Abstract][Full Text] [Related]
25. Eosinophils and Chronic Respiratory Diseases in Hospitalized COVID-19 Patients.
Valverde-Monge M; Cañas JA; Barroso B; Betancor D; Ortega-Martin L; Gómez-López A; Rodríguez-Nieto MJ; Mahíllo-Fernández I; Sastre J; Del Pozo V
Front Immunol; 2021; 12():668074. PubMed ID: 34149705
[TBL] [Abstract][Full Text] [Related]
26. Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: Results of a real-world study.
Yang H; Wang Z; Jiang C; Zhang Y; Zhang Y; Xu M; Zhang Y; Wang Y; Liu X; An Z; Tong Z
J Med Virol; 2023 Jul; 95(7):e28947. PubMed ID: 37470209
[TBL] [Abstract][Full Text] [Related]
27. All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis.
Chen R; Guo Y; Deng S; Wang J; Gao M; Han H; Wang L; Jiang H; Huang K
Cardiol Plus; 2023; 8(2):103-110. PubMed ID: 37539021
[TBL] [Abstract][Full Text] [Related]
28. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
[TBL] [Abstract][Full Text] [Related]
29. Relationship between blood eosinophil levels and COVID-19 mortality.
Yan B; Yang J; Xie Y; Tang X
World Allergy Organ J; 2021 Mar; 14(3):100521. PubMed ID: 33589865
[TBL] [Abstract][Full Text] [Related]
30. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
[No Abstract] [Full Text] [Related]
31. The Effect of Eosinopenia on Mortality in Patients with Intracerebral Hemorrhage.
Bolayir A; Cigdem B; Gokce SF; Bolayir HA; Kayim Yildiz O; Bolayir E; Topaktas SA
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2248-2255. PubMed ID: 28733122
[TBL] [Abstract][Full Text] [Related]
32. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19.
Hu CY; Cui WS; Lei Y; Tang YW; Zhang YY; Su QM; Peng F; Zeng YF; Song JL; Luo CN; Zhou Y; Li XY; Zhao ZX
Infect Drug Resist; 2023; 16():7797-7808. PubMed ID: 38148771
[TBL] [Abstract][Full Text] [Related]
34. Admission blood eosinophil count, inpatient death and death at 1 year in exacerbating patients with COPD.
Echevarria C; Steer J; Prasad A; Quint JK; Bourke SC
Thorax; 2023 Nov; 78(11):1090-1096. PubMed ID: 37487711
[TBL] [Abstract][Full Text] [Related]
35. Eosinopenia as a diagnostic marker of bloodstream infection in a general internal medicine setting: a cohort study.
Hirosawa T; Harada Y; Morinaga K; Takase H; Nin M; Shimizu T
BMC Infect Dis; 2020 Jan; 20(1):85. PubMed ID: 32000694
[TBL] [Abstract][Full Text] [Related]
36. Prognostic usefulness of eosinopenia in the pediatric intensive care unit.
Kim YH; Park HB; Kim MJ; Kim HS; Lee HS; Han YK; Kim KW; Sohn MH; Kim KE
J Korean Med Sci; 2013 Jan; 28(1):114-9. PubMed ID: 23341721
[TBL] [Abstract][Full Text] [Related]
37. Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study.
Zong K; Zhou H; Li W; Jiang E; Liu Y; Li S
Acta Pharm Sin B; 2023 Nov; 13(11):4655-4660. PubMed ID: 37969737
[TBL] [Abstract][Full Text] [Related]
38. [Relevance of eosinopenia as marker of sepsis in the Emergency Department].
Lavoignet CE; Le Borgne P; Slimani H; Forato M; Kam C; Kauffmann P; Lefebvre F; Bilbault P
Rev Med Interne; 2016 Nov; 37(11):730-734. PubMed ID: 27032483
[TBL] [Abstract][Full Text] [Related]
39. Low albumin combined with low-molecular-weight heparin as risk factors for liver injury using azvudine: Evidence from an analysis of COVID-19 patients in a national prospective pharmacovigilance database.
Lu H; Zeng Y; Shi QZ; Liu L; Gong YQ; Li S; Yan P
Int J Clin Pharmacol Ther; 2024 May; 62(5):222-228. PubMed ID: 38431833
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial.
Tian X; Xu Y; Wang L; Dong C; Yan X; Fan J; Xie H; Zhang H; Wang J; Liu Y; Wang Y; Pan S; Wu A; Liu X; Yao C; Wang M
Trials; 2024 Jan; 25(1):77. PubMed ID: 38254211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
